Formal post-publication commentary on published papers can involve challenges, clarifications or, in some cases, replication of the published work and may, after peer review, be published online ...

Formal post-publication commentary on published papers can involve challenges, clarifications or, in some cases, replication of the published work and may, after peer review, be published online ...

The peer review process is central to science – but it can be easily manipulated. Improving it is vital to uphold research ...

Traditional forms of peer review occur before a paper is published. Both reviewers and authors remain anonymous. Different disciplines take a slightly different approach to the review process.

If you currently have a manuscript in peer review, you will see a status message on your Author Dashboard ... Suggest potential reviewers Make a decision on the paper without further review (the ...

Traditional forms of peer review occur before a paper is published. Both reviewers and authors remain anonymous. Different disciplines take a slightly different approach to the review process.

Suggest potential reviewers Make a decision on the paper without further review (the manuscript will move to step 7 ... the SME will evaluate the revised manuscript and either request further peer ...

Sakana said it collaborated with researchers at the University of British Columbia and the University of Oxford to submit ...

Several AI academics took to social media to criticize Intology and Autoscience’s stunts as a co-opting of the scientific peer review process. “All these AI scientist papers are using peer ...

An independent Jury will choose the winning work among the high-quality empirical research papers in biomedicine published from 2016 onwards in peer-reviewed journals. The articles should be nominated ...

Japanese tech startup Sakana AI has written the first Artificial Intelligence (AI) generated peer-reviewed scientific paper, the company announced Wednesday. “We’re proud to announce that a ...

DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that the ...